Saba Capital Management’s AEON Biopharma AEON Stock Holding History

Saba Capital Management’s Portfolio AEON Stock Details AEON Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q3	–	Sell	-3,281	Closed	-$2.49M	–	574
2023 Q2	$2.49M	Hold	3,281	–	–	0.06%	206
2023 Q1	$2.4M	Sell	3,281 -4,348	-57%	-$3.16M	0.05%	320
2022 Q4	$5.52M	Hold	7,629	–	–	0.07%	382
2022 Q3	$5.41M	Hold	7,629	–	–	0.06%	504
2022 Q2	$5.39M	Buy	7,629 +417	+6%	+$294K	0.06%	499
2022 Q1	$5.08M	Buy	7,212 +6,004	+497%	+$4.21M	0.07%	435
2021 Q4	$845K	Hold	1,208	–	–	0.01%	608
2021 Q3	$848K	Buy	1,208 +437	+57%	+$305K	0.02%	447
2021 Q2	$535K	Buy	+771	New	+$539K	0.02%	389

Other funds holding AEON

ACM

Atalaya Capital Management New York $45M AUM 3.02% 1-Year Est. Return

RCM

Rivernorth Capital Management West Palm Beach, Florida $2.1B AUM 2.15% 1-Year Est. Return

Ikarian Capital Dallas, Texas $928M AUM 596.14% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

FAM

Formidable Asset Management Cincinnati, Ohio $629M AUM 15.56% 1-Year Est. Return

BFM

Boothbay Fund Management New York $7.6B AUM 109.3% 1-Year Est. Return

Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return

Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

Saba Capital Management's AEON Position: Q3 2023 in Review

Saba Capital Management sold out of AEON Biopharma (AEON) in Q3 2023, closing a stake of 3,281 shares — an estimated $2.49M sold.

Saba Capital Management first reported a position in AEON in Q2 2021 and held it in 9 quarters. The position peaked at $5.52M in Q4 2022. 15 funds tracked by Wall St. Rank hold AEON as of Q3 2023.

Saba Capital Management reported no remaining AEON Biopharma position as of Q3 2023 after selling out during the quarter.
Saba Capital Management sold 3,281 AEON Biopharma shares in Q3 2023, an estimated $2.49M.
Saba Capital Management first reported a position in AEON Biopharma in Q2 2021 and held it in 9 quarters.
Saba Capital Management's AEON Biopharma position peaked at $5.52M in Q4 2022.
15 funds tracked by Wall St. Rank held AEON Biopharma as of Q3 2023.

Based on Saba Capital Management's 13F filing for Q3 2023, filed 14 Nov 2023.